EMX2 inhibits clear cell renal cell carcinoma progress via modulating Akt/FOXO3a pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Empty spiracles homeobox 2 (EMX2) is crucial for neuronal development but its role in clear cell renal cell carcinoma (ccRCC) is largely unknown.
• Emerging evidence suggests EMX2 functions as a tumor suppressor, prompting investigation into its specific mechanisms in ccRCC.

Purpose of the Study:

• To elucidate the role and underlying molecular mechanisms of EMX2 in regulating ccRCC progression.
• To determine the relationship between EMX2 expression levels and patient prognosis in ccRCC.

Main Methods:

• Quantitative analysis of EMX2 expression in ccRCC tissues and cell lines.
• In vitro assays (cell growth, migration, invasion) and in vivo studies (tumor growth in nude mice) to assess EMX2 function.
• Investigation of the Akt/FOXO3a signaling pathway, including protein phosphorylation, expression levels, and interactions, using techniques like Western blotting and shRNA-mediated knockdown.

Main Results:

• EMX2 expression was significantly downregulated in ccRCC tissues and cell lines, with low expression correlating with poor patient prognosis.
• Overexpression of EMX2 suppressed ccRCC cell proliferation, migration, and invasion in vitro and inhibited tumor growth in vivo.
• EMX2 exerted its tumor-suppressive effects by attenuating Akt phosphorylation and increasing FOXO3a expression, thereby inhibiting the Akt/FOXO3a signaling pathway.

Conclusions:

• EMX2 functions as a tumor suppressor in ccRCC by inhibiting cell growth, migration, invasion, and tumor progression.
• The Akt/FOXO3a signaling pathway is a key mediator of EMX2's tumor-suppressive activity in ccRCC.
• EMX2 represents a potential therapeutic target for ccRCC treatment.